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Summary. The metabolic fate of furosemide was 
studied in kidney transplant patients after oral and 
intravenous administration of the diuretic at therap- 
eutic doses. Serial urine samples were collected over 
a 24 h period and furosemide was analyzed by a spe- 
cific high performance liquid chromatographic 
method using fluorescence detection. We found 
no evidence of the putative furosemide metabo- 
lite, 2-amino-4-chloro-5-sulfamoylanthranilic acid 
(CSA), in any of the samples analyzed. The amount 
of furosemide excreted as the glucuronide metabo- 
lite accounted for 8% of the available dose, whether 
administered orally or by intravenous infusion. In 
addition, the significant positive correlation observ- 
ed between the percent of the available dose excreted 
as furosemide glucuronide and the renal clearance of 
furosemide (r= 0.581, p < 0.02) suggests that the glu- 
curonidation process for furosemide may be occur- 
ring in the  kidney. Furosemide and its glucuronide 
metabolite accounted for only 45% of the intrave- 
nous dose recovered in the urine. Biliary excretion of 
unchanged furosemide and/or  furosemide glucuro- 
nide into the feces probably accounts for the remain- 
der of the dose not recovered. 
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The metabolism of furosemide has been studied in 
healthy volunteers and in various patient popula- 
tions [1, 2], but not in kidney transplant patients. In 
addition, the data concerning the metabolic fate of 
furosemide is controversial, as reviewed in Refer- 
ences [1] and [3]. While some investigators have re- 
ported 2-amino-4-chloro-5-sulfamoylanthranilic ac- 
id (CSA) to be a metabolite of furosemide, others 
have not confirmed this finding. A glucuronide me- 
tabolite of furosemide has also been reported, al- 
though poorly quantitated in some studies, and 
found to vary with dosing history and renal function 
in others. These discrepancies may reflect problems 
inherent in the assay procedures as reported by 
Smith et al. [3]. The present investigation was, there- 
fore, undertaken in order to define, in kidney trans- 
plant patients, the metabolism of furosemide using a 
specific high performance liquid chromatographic 
(HPLC) assay. 
Materials and Methods 
Furosemide tablets (40 mg, lot # 6015 49) and intra- 
venous solution (10mg/ml, lot # 's X61922 and 
613379) were obtained from Hoechst-Roussel 
Pharmaceuticals, Inc. (Somerville, NJ). All other 
drugs and reagents used in the analytical methods 
were identical to those previously described [3, 4]. 
Patient Studies 
Characteristics of the 8 kidney transplant patients 
studied were previously described and the pharma- 
cokinetics and pharmacodynamics of furosemide in 
this patient population were evaluated [4]. After an 
overnight fast, each patient received either an oral or 
intravenous dose of furosemide at approximately 
8 a.m. Furosemide tablets were taken with water or 
fruit juice while the solution was infused intrave- 
nously over a 10min period. In addition, patients 
fasted for at least 2 h after oral administration of fu- 
rosemide. Voided urine was collected hourly from 
1 h prior to dosing until 8 h after dosing, and then 
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Table1. Urinary excretion a of furosemide and its conjugated 
metabolite in kidney transplant patients 













120 mg p. o. 
120 mg i.v. 
120mg p.o. 
120 mg x.v. 
120 mg p. o. 
120mg i.v. 
120 mg p. o. 
120 mg i.v. 
40mg p.o. 
40 mg i.v. 
80mg p.o. 
80 mg i.v. 
80mg p.o. 
80mg Lv. 
21.2 3.2 2.7 
28.2 7.6 4.8 
9.7 3.6 9.9 
32.6 9.7 8.1 
31.0 8.9 9.1 
41.8 8.4 7.0 
17.2 1.8 3.5 
43.6 5.9 4.9 
16.1 2.4 5.2 
40.3 2.4 2.0 
8.5 2.9 15.0 
16.1 3.9 9.8 
31.9 4.5 10.3 
56.7 8.2 10.2 
20.7 6.0 13.6 
34.6 8.5 10.6 
Mean p.o. 8.7 
+ SD (4.5) 
Mean i.v. 7.2 
_+ SD (3.1) 
a Collection period of 24 h; b Values were previously reported [4]; 
c Expressed in furosemide weight units 
pooled from 8 to 24 h. The kidney transplant patients 
were studied on consecutive days after oral and in- 
travenous dosing of furosemide, respectively. All 
patients signed the 'Consent Form' approved by the 
Human Research Committee of the University of 
California, San Francisco. 
Analytical Methods 
Urine samples were measured in parallel for un- 
changed furosemide and its glucuronide metabolite 
using HPLC with fluorescence detection as previ- 
ously described [3]. Duplicate urine samples 
(0.20 ml) were prepared and added to 0.80 ml buffer 
solutions (0.1 M sodium acetate pH 4.5), one con- 
taining 2000units fl-glucuronidase and the other 
containing only buffer. The difference in furosemide 
concentration between urine samples with and with- 
out fl-glucuronidase was used as a measure of the 
metabolite concentration (expressed in furosemide 
weight units). Complete conversion of furosemide 
glucuronide to the parent drug was demonstrated 
since identical results were obtained over a 100-fold 
enzyme concentration range (100-10,000units/ 
0.20 ml urine sample). 
Urine samples were analyzed for CSA by HPLC 
with fluorescence detection as previously reported 
[3]. The sensitivity for this direct injection method is 
2.5 p.g/ml using 0.05 ml urine samples. 
Calculations 
The percent of the available dose of furosemide ex- 
creted as the glucuronide metabolite, FGL, was esti- 
mated by: 
F G L =  100 x [(Ae=)enzyme- (Ae =) no enzyme]/ 
F x DOSE 
where the amount of unchanged drug recovered in 
the urine at time infinity after treatment with fl-glu- 
curonidase is represented by (Ae =) enzyme. The 
amount of unchanged drug recovered in the urine af- 
ter treatment with buffer is represented by (Ae =) no 
enzyme. The extent of availability, F, was previously 
reported [4] for oral doses in these patients and as- 
sumed to be equal to one for all intravenous doses. 
The above equation assumes a negligible first-pass 
effect for the metabolism of furosemide to its glucu- 
ronide metabolite, as will be discussed subsequently. 
Results 
The putative metabolite of furosemide, CSA, was 
sought in the urine samples for all 8 kidney trans- 
plant patients after both oral and intravenous admin- 
istration. We found no evidence of this metabolite in 
any of the samples analyzed. 
Table 1 lists the urinary excretion of furosemide 
and its glucuronide metabolite after both oral and in- 
travenous treatments. Urinary recovery of the parent 
compound and metabolite accounted for only 
45.2 _+ 17.4% of the intravenous dose. The amount of 
furosemide excreted as the glucuronide metabolite 
was approximately 8% of the available dose and var- 
ied considerably between patients, as reflected by a 
coefficient of variation of almost 50%. Nevertheless, 
in Fig. 1 a significant positive correlation was ob- 
served between the % of the available dose excreted 
as furosemide glucuronide and the renal clearance of 
furosemide in the 8 kidney transplant patients stud- 
ied (r=0.581; p<0.02). In addition, no significant 
difference was found in the % of the available dose 
excreted as furosemide glucuronide with respect to 
route of administration (8.7 +4.5% for p.o. versus 
7.2 ___ 3.1% for i. v.; p >  0.10; paired t-test). In our pre- 
vious report [4] the patients listed in Table I were de- 
fined as furosemide responders (patients S J, PD, WJ 
and FR) and non-responders based on the dose of 
drug required to elicit the desired diuretic effect. 
Although there was a tendency for an increased % 
of the available dose to be excreted as furosemide 
glucuronide in the responders (9.6+4.2% versus 
6.3 +2.7%), this difference was not significant (p> 
0.05; unpaired t-test). 









I ............. I ; C )  ..... I l I ......... 
10 20 40 50 60 70 
CLR (ML/MI N) 
Fig. 1. Correlation between the percent of the available dose of fu- 
rosemide excreted as glucuronide metabolite (FGL) and furose- 
mide renaI clearance (CLr) after oral (O) and intravenous (11) 
dosing of furosemide to kidney transplant patients (r=0.581, 
p < 0.02) 
Discussion 
Conflicting results concerning the metabolism of fu- 
rosemide to CSA probably reflect problems inherent 
in the assay method. Smith et al. [3] clearly demon- 
strate that CSA is not formed in vivo, but is an ana- 
lytical artifact formed during an acid extraction 
procedure. Using a direct injection assay method, 
without prior extraction and/or  derivatization, 
Smith et al. [3] found no evidence of CSA in 9 
healthy volunteers studied following intravenous 
and oral dosing. In the present study, the putative 
metabolite of furosemide, CSA, was not detected in 
the urine samples of kidney transplant patients. This 
finding supports the contention [3] that CSA is not a 
metabolite of  furosemide. 
The significant positive correlation between the 
% of the available dose excreted as furosemide glu- 
curonide and the renal clearance of furosemide 
(Fig. 1) suggests that the biotransformation of furose- 
mide to its glucuronide metabolite may be occuring 
in the kidney. This hypothesis is supported by the 
fact that the ratio of the amount of furosemide glucu- 
ronide to unchanged furosemide in the urine is simi- 
lar for kidney transplant patients (0.23_+0.10 for 
p.o.; 0.21 + 0.08 for i.v.) and healthy volunteers 
(0.22 _+ 0.05 for p. o.; 0.21 + 0.04 for i. v.; [3]). In addi- 
tion, no significant difference was observed in the % 
of the available dose of furosemide excreted as glu- 
curonide metabolite, whether the drug was adminis- 
tered orally or intravenously to kidney transplant 
patients and healthy volunteers. This implies that the 
first-pass effect for hepatic and gut wall metabolism 
to its glucuronide metabolite is probably negligible. 
This is consistent with the recent finding of Verbeeck 
et al. [5] which indicates that the liver does not play a 
significant role in the nonrenal clearance of furose- 
mide in the dog. In contrast to the results reported 
here, Andreasen et al. [6] demonstrated a highly sig- 
nificant negative correlation between drug serum 
clearance and the fraction of furosemide excreted as 
glucuronide in patients with severe arterial hyperten- 
sion, which would seem to indicate that greater me- 
tabolism results from prolonged drug residence in 
the body. Our calculations of their data show that a 
highly negative correlation also exists between renal 
clearance and the fraction excreted as furosemide 
glucuronide. However, these earlier results may be 
influenced by analytical problems since more recent- 
ly Andreasen et al. [7] reported furosemide glucuro- 
nide levels in healthy volunteers which were in 
marked contrast to the data published earlier using 
TLC separation. 
Total urinary recovery of furosemide and its glu- 
curonide metabolite accounted for only 45% of the 
intravenous dose (versus 80% in normal volunteers). 
The remainder of the dose was probably excreted in- 
to the feces via the biliary route, either as unchanged 
furosemide and/or  furosemide glucuronide. This is 
consistent with previous studies [8, 9] which demon- 
strate that over 60% of furosemide-S 3s can be recov- 
ered in the feces after intravenous administration of 
drug to patients with impaired renal functions. 
Acknowlegdements. We are indebted to Dr. 
J. G. Gambertoglio and Dr. F. Vincenti for their ini- 
tiative and provision of the patient population for 
these studies. The authors are most appreciative of 
the help given by Ms. J. Almeida in preparation of 
the manuscript. 
This work was supported in part by NIH Grant 
AM 20884 and by the Earl C. Anthony Fund. During 
the course of this work D. E. S. was supported as an 
NIH Predoctoral Scholar on NIH Training Grant 
GM 07175. 
References 
1. Benet LZ (t979) Pharmacokinetics/pharmacodynamics of fu- 
rosemide in man: A review. J Pharmacokinet Biopharm 7:1-27 
790 D.E. Smith and L.Z. Benet: Furosemide in Kidney Transplant Patients 
2. Cutler RE, Blair AD (1979) Clinical pharmacokinetics of fu- 
rosemide. Clin Pharmacokinet 4:279-296 
3. Smith DE, Lin ET, Benet LZ (1980) Absorption and disposition 
of furosemide in healthy volunteers, measured with a metabo- 
lite specific assay. Drug Metab Dispos 8: 337-342 
4. Smith DE, Gambertoglio JG, Vincenti F, Benet LZ (1981) Fu- 
rosemide kinetics and dynamics after kidney transplant. Clin 
Pharmacol Ther 30:105-113 
5. Verbeeck RK, Gerkens JF, Wilkinson GR, Branch RA (1981) 
Disposition of furosemide in functionally hepatectomized dogs. 
J Pharmacol Exp Ther 216:479-483 
6. Andreasen F, Pedersen OL, Mikkelsen E (1978) Distribution, 
elimination and natriuretic effect of furosemide in patients with 
severe arterial hypertension. Eur J Clin Pharmacol 4:237-244 
7. Andreasen F, Christensen CK, Jakobsen FK, Morgensen CE 
(1981) The use of HPLC to elucidate the metabolism and uri- 
nary excretion of furosemide and its metabolic products. Acta 
Pharmacol Toxico149: 223-229 
8. Beermann B, Dal6n E, Lindstr6m B (1977) Elimination of fu- 
rosemide in healthy subjects and in those with renal failure. 
Clin Pharmacol Ther 22:70-78 
9. Rupp W (1974) Pharmacokinefics and pharmacodynamics of 
lasix. Scot Med J 19:5-13 
Received: March 9, 1981 
in revised form: September 1, 1982 
accepted: March 4, 1983 
Leslie Z. Benet, Ph. D. 
Department of Pharmacy 
School of Pharmacy, 926-S 
University of California 
San Francisco, California 94143, USA 
